Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not have an impact on its operating profit for 2025. “Sanofi is picking up the ...

Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, ...

Bank of America cut its rating on Novavax (NASDAQ:NVAX) to Underperform from Neutral and lowered its price objective to $7 from $9, saying recent gains in the shares have overrun a still uncertain ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

The EUL has been granted for the Nuvaxovid COVID-19 Vaccine, a novel recombinant, adjuvanted SARS-CoV-2 rS vaccine, which is to be marketed by Novavax in Europe and other markets.

The EC granted CMA for Nuvaxovid to prevent COVID-19 in individuals aged 18 and over in December 2021. In addition to the EC's expanded CMA, India has granted emergency use authorization in the 12 ...

In the pediatric expansion, Nuvaxovid achieved its primary efficacy endpoint with clinical efficacy of 78.29% (95% CI: 37.55%, 92.45%) overall at a time when the Delta variant was the predominant ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given ...

STATEN ISLAND, N.Y. — The World Health Organization (WHO) issued an emergency use listing (EUL) for another coronavirus (COVID-19) vaccine — Nuvaxovid — it was announced Tuesday. The new ...